Inter-American Development Bank
facebook
twitter
youtube
linkedin
instagram
Abierto al públicoBeyond BordersCaribbean Development TrendsCiudades SosteniblesEnergía para el FuturoEnfoque EducaciónFactor TrabajoGente SaludableGestión fiscalGobernarteIdeas MatterIdeas que CuentanIdeaçãoImpactoIndustrias CreativasLa Maleta AbiertaMoviliblogMás Allá de las FronterasNegocios SosteniblesPrimeros PasosPuntos sobre la iSeguridad CiudadanaSostenibilidadVolvamos a la fuente¿Y si hablamos de igualdad?Home
Citizen Security and Justice Creative Industries Development Effectiveness Early Childhood Development Education Energy Envirnment. Climate Change and Safeguards Fiscal policy and management Gender and Diversity Health Labor and pensions Open Knowledge Public management Science, Technology and Innovation  Trade and Regional Integration Urban Development and Housing Water and Sanitation
  • Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer

Gente Saludable

IDB

  • HOME
  • CATEGORIES
    • Aging and Dependency
    • Courses and Seminars
    • Digital Transformation
    • Public health and nutrition
    • Healthy Lifestyle
    • Health services
    • Health Spending and Financing
    • Women’s and Children’s Health
  • authors
  • English
    • Spanish
    • Portuguese
regional regulatory agency

Would a Regional Regulatory Agency for Health Technologies be Feasible?

July 31, 2018 por Autor invitado 1 Comment


Regulatory agencies around the world are continuously reviewing requests for the commercialization of new medicines and other health technologies in their countries. With globalization, technological advances and innovation, and the emergence of new types of treatments, such as biologicals, biosimilars, and cell and gene therapies, the volume and complexity of such requests have increased significantly and will continue to rise. This adds pressure to the capacity of most national regulatory agencies. For example, the Brazilian Health Regulatory Agency (ANVISA) receives almost 1,000 approval requests for new drugs every year.

These institutions must respond to all demands in a timely and technically robust manner to facilitate people’s access to innovative therapies and potentially life-saving medications. In order to analyze the quality, safety, and efficacy of new medicines, they require extremely qualified personnel (in sufficient numbers), continuous education and training, good infrastructure, and the latest equipment and technology to keep up with innovations in the pharmaceutical world. They also need to routinely develop and/or update policies, regulations, and procedures, and ensure their application.

All these tasks demand adequate funding, which presents a challenge for most countries. According to the World Health Organization, at least three out of every ten national regulatory agencies in the world are deficient, largely due to limited resources. Resource challenges and administrative bottlenecks appear even in high-income countries

“due to the increasingly globalized nature of pharmaceutical manufacture and trade, and the emergence of innovative products (…) which require new regulatory know-how and approaches.”

How can regulatory agencies keep up with the increasing volume and complexity of requests?

Diverse initiatives to harmonize regulations and procedures amongst different regulatory agencies have arisen around the world. These initiatives aim to improve efficiency and reduce costs to governments by:

  • harmonizing quality standards, technical guidelines, and requirements for product registration
  • facilitating information and knowledge exchange amongst agencies
  • reducing duplication in testing, reporting, and paperwork related to submissions
  • defining international priorities and common-agendas
  • expediting the entry of new products into the market.

In 1995, a new initiative in Europe moved beyond harmonization efforts. A regional regulatory agency, the European Medicines Agency (EMA), was created to centralize the approval process for the commercialization of certain medicines in the European market. EMA changed the rules of the game by allowing the industry to prepare and submit one application process for all members of the European Union (EU) at the same time. EMA evaluates each application with the support of a network of experts from the region and makes a recommendation to the European Commission. If approved, the commercialization of the health technology is authorized for all members of the EU.

A regional regulatory agency in Latin America and the Caribbean?

Many initiatives in the region aim to harmonize regulations and procedures, with varying levels of success, but none has concretely proposed the establishment of a regional body, following the EMA model.

The creation of EMA has brought many benefits to governments, primarily by:

  • promoting the pooling of resources and lessening the administrative burden of countries
  • encouraging work coordination and expediting the exchange of important information on medicines between countries
  • providing independent, science-based information on medicines to patients, healthcare professionals, the industry, and governments, using rigorous and consistent standards and the best available expertise.

Creating a regulatory agency would have many advantages for the region, especially for countries that haven’t experienced much progress in terms of drug regulation and/or the regulation of other health technologies, such as medical devices and herbal medicines.

This agency could be implemented in sub-regions – across economic integration blocks, for instance – or focus on specific technologies such as medical devices, where there has been limited progress in most countries and which will require even more resources and know-how.

There are challenges to overcome, no doubt. Some of the difficulties experienced by countries in harmonization efforts would likely play an even greater role here, such as national differences in patent laws and adherence to international guidelines, levels of evidence required for the approval of distinct types of drugs, strength of post-marketing surveillance and pharmacovigilance, and enforcement capabilities, among others. Additionally, there would be more “practical” challenges related to location, financing, operational norms and procedures, etc. But these are not impossible barriers to overcome, and, in the long run, chances are that benefits will outdo the costs.

As countries in the region and the world face continuous pressure over public health budgets, innovative solutions to optimize the use of scarce resources should be discussed and debated by all interested stakeholders across nations. Uniting efforts to deliver quality, safe, and effective medicines for their citizens should be top in governments’ priority agendas.

How does the regulatory health agency in your country work? Do you think a regional regulatory agency is a realistic possibility? Tells us in the comments section or mention @BIDgente on Twitter.

Marcella Distrutti is a Health Specialist at the Social Protection and Health Division of the Inter-American Development Bank.

Indhira Ramírez is a Consultant the Social Protection and Health Division of the Inter-American Development Bank.

Red CRITERIA is an InterAmerican Development Bank (IDB) initiative whose goal is to support Latin American and Caribbean countries in strengthening their policies in prioritization of health spending as well as in the design and adjustment of their health benefits plans. To join this network, subscribe here. 
Lee en español.

Filed Under: Uncategorized

Autor invitado

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Follow Us

Subscribe

Search

Health

Latin American and Caribbean countries face multiple challenges to provide quality healthcare for their citizens. In this blog, IDB Specialists and international experts discuss current health issues and hope to build a dynamic dialogue through your comments.

Similar Posts

  • How Perspective Shapes Health Policies
  • We invite you to see the material of our Regional Policy Dialogue 2019: A regional debate on long-term care systems
  • The Centralized Drug Price Negotiation Process and its Collateral “Benefits”
  • 300+ Economists around the World ask for “Health for All”
  • Professional Midwives to the Rescue

Footer

Banco Interamericano de Desarrollo
facebook
twitter
youtube
youtube
youtube

    Blog posts written by Bank employees:

    Copyright © Inter-American Development Bank ("IDB"). This work is licensed under a Creative Commons IGO 3.0 Attribution-NonCommercial-NoDerivatives. (CC-IGO 3.0 BY-NC-ND) license and may be reproduced with attribution to the IDB and for any non-commercial purpose. No derivative work is allowed. Any dispute related to the use of the works of the IDB that cannot be settled amicably shall be submitted to arbitration pursuant to the UNCITRAL rules. The use of the IDB's name for any purpose other than for attribution, and the use of IDB's logo shall be subject to a separate written license agreement between the IDB and the user and is not authorized as part of this CC- IGO license. Note that link provided above includes additional terms and conditions of the license.


    For blogs written by external parties:

    For questions concerning copyright for authors that are not IADB employees please complete the contact form for this blog.

    The opinions expressed in this blog are those of the authors and do not necessarily reflect the views of the IDB, its Board of Directors, or the countries they represent.

    Attribution: in addition to giving attribution to the respective author and copyright owner, as appropriate, we would appreciate if you could include a link that remits back the IDB Blogs website.



    Privacy Policy

    Derechos de autor © 2025 · Magazine Pro en Genesis Framework · WordPress · Log in

    Banco Interamericano de Desarrollo

    Aviso Legal

    Las opiniones expresadas en estos blogs son las de los autores y no necesariamente reflejan las opiniones del Banco Interamericano de Desarrollo, sus directivas, la Asamblea de Gobernadores o sus países miembros.

    facebook
    twitter
    youtube
    This site uses cookies to optimize functionality and give you the best possible experience. If you continue to navigate this website beyond this page, cookies will be placed on your browser.
    To learn more about cookies, click here
    X
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT